Federal Register of Legislation - Australian Government

Primary content

PB 87 of 2015 Arrangements as amended, taking into account amendments up to National Health (Botulinum Toxin Program) Amendment Special Arrangement 2022
Administered by: Health and Aged Care
Registered 24 Jan 2023
Start Date 01 Jan 2023

Commonwealth Coat of Arms of Australia

National Health (Botulinum Toxin Program) Special Arrangement 2015

PB 87 of 2015

made under subsections 100(1) and (2) of the

National Health Act 1953

Compilation No. 4

Compilation date:                              1 January 2023

Includes amendments up to:            F2022L01702

Registered:                                         24 January 2023

About this compilation

This compilation

This is a compilation of the National Health (Botulinum Toxin Program) Special Arrangement 2015 that shows the text of the law as amended and in force on 1 January 2023 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

  

  

  


Contents

Part 1—Preliminary                                                                                                                                        1

1............ Name of Special Arrangement....................................................................................... 1

4............ Definitions..................................................................................................................... 1

Part 2—Pharmaceutical benefits covered by this Special Arrangement                        2

5............ Pharmaceutical benefits covered by this Special Arrangement...................................... 2

6............ Application of Part VII of the Act................................................................................. 2

7............ Section 100 only supply................................................................................................ 3

Part 3—Entitlement to pharmaceutical benefits                                                                           4

8............ Eligible persons............................................................................................................. 4

Part 4—Supply of pharmaceutical benefits                                                                                     5

9............ Who can supply pharmaceutical benefits....................................................................... 5

Part 5—Administration of pharmaceutical benefits                                                                   6

10.......... Requirements for administering pharmaceutical benefits under this Special Arrangement       6

11.......... Eligible medical practitioner........................................................................................... 6

12.......... Registered practice location........................................................................................... 6

Part 6—Payment amounts                                                                                                                          7

Division 1—Payments to suppliers that are approved hospital authorities for public hospitals              7

13.......... Payments to approved hospital authorities for public hospitals..................................... 7

Division 2—Payments to suppliers that are approved hospital authorities for private hospitals            7

14.......... Payments to approved hospital authorities for private hospitals.................................... 7

Part 7—Dispensed price                                                                                                                               8

Division 1—Dispensed price for supply of a pharmaceutical benefit by a hospital authority for a public hospital                                                                                                                                 8

15.......... The dispensed price—supply by public hospital........................................................... 8

16.......... Where quantity is less than a pack quantity................................................................... 8

Division 2—Dispensed price for supply of a pharmaceutical benefit by certain suppliers          8

17.......... The dispensed price—supply by an approved hospital authority for a private hospital. 8

18.......... Mark‑up........................................................................................................................ 9

19.......... Where quantity is less than a pack quantity................................................................. 10

20.......... Dispensing fee............................................................................................................. 10

21.......... Rounding up of dispensed price.................................................................................. 11

Part 8—Patient contributions                                                                                                                 12

22.......... Patient contributions in relation to approved hospital authorities................................. 12

Schedule 1—Pharmaceutical benefits to which this Special Arrangement applies 13

Endnotes                                                                                                                                                               14

Endnote 1—About the endnotes                                                                                                      14

Endnote 2—Abbreviation key                                                                                                          15

Endnote 3—Legislation history                                                                                                       16

Endnote 4—Amendment history                                                                                                     17

 


Part 1Preliminary

  

1  Name of Special Arrangement

             (1)  This Special Arrangement is the National Health (Botulinum Toxin Program) Special Arrangement 2015.

             (2)  This Special Arrangement may also be cited as PB 87 of 2015.

4  Definitions

                   In this Special Arrangement:

Act means the National Health Act 1953.

approved hospital means a hospital in respect of which the hospital authority is approved under section 94 of the Act.

approved hospital authority has the meaning given by subsection 84(1) of the Act.

approved pharmacist has the meaning given by subsection 84(1) of the Act.

eligible medical practitioner has the meaning given by section 11.

eligible patient means a person who, under subsection 8(1), is eligible to receive a pharmaceutical benefit.

medical practitioner has the same meaning as in subsection 3(1) of the Health Insurance Act 1973.

other Special Arrangement means another Special Arrangement under section 100 of the Act.

provider number has the same meaning as in section 4 of the Health Insurance Regulations 2018.

registered practice location has the meaning given by section 12.

Regulations means the National Health (Pharmaceutical Benefits) Regulations 2017

Note:          Terms used in this Special Arrangement have the same meaning as in the Act—see section 13 of the Legislative Instruments Act 2003. These terms include:

·      pharmaceutical benefit

·      public hospital

Part 2Pharmaceutical benefits covered by this Special Arrangement

5  Pharmaceutical benefits covered by this Special Arrangement

             (1)  This Special Arrangement applies to each pharmaceutical benefit mentioned in Schedule 1.

             (2)  Each pharmaceutical benefit is a brand of a listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Note:          Each listed drug mentioned in Schedule 1 has been declared by the Minister under subsection 85(2) of the Act. The form, manner of administration and brand mentioned in Schedule 1 have been determined by the Minister under subsections 85(3), (5) and (6) of the Act respectively.

6  Application of Part VII of the Act

             (1)  Each pharmaceutical benefit supplied in accordance with this Special Arrangement is supplied under Part VII of the Act.

             (2)  A provision of Part VII of the Act, or of regulations or other instruments made for Part VII of the Act, applies, subject to this Special Arrangement.

Note:          See subsection 100(3) of the Act.

             (3)  If a pharmaceutical benefit is supplied in accordance with this Special Arrangement, regulations 48, 49 and 55 of the Regulations do not apply to the supply.

             (4)  For the purposes of paragraph 40 of the Regulations, a pharmaceutical benefit to be supplied to a person in accordance with this Special Arrangement is taken to be the same as, or equivalent to, another pharmaceutical benefit to be supplied to that person in accordance with this Special Arrangement only if:

                     (a)  the prescriptions for the supply of both benefits relate to moderate to severe spasticity of the upper limb (whether or not following a stroke); or

                     (b)  the prescriptions for the supply of both benefits relate to urinary incontinence; or

                     (c)  the prescriptions for the supply of both benefits relate to spasmodic torticollis; or

                     (d)  the prescriptions for the supply of both benefits relate to dynamic equinus foot deformity; or

                     (e)  the prescriptions for the supply of both benefits relate to blepharospasm; or

                      (f)  the prescriptions for the supply of both benefits relate to hemifacial spasm; or

                     (g)  the prescriptions for the supply of both benefits relate to chronic migraine; or

                     (h)  the prescriptions for the supply of both benefits relate to severe primary axillary hyperhidrosis; or

                      (i)  the prescriptions for the supply of both benefits:

                              (i)  are written in circumstances, determined by the Minister under paragraph 85(7)(b) of the Act, that have the same circumstances code (within the meaning of the Minister’s determination); and

                             (ii)  are not prescriptions of a kind referred to in paragraphs (a) to (h) of this subsection.

7  Section 100 only supply

             (1)  If the letter ‘D(100)’ is mentioned in the column in Schedule 1 headed ‘Section 100 only’ for a listed drug, the listed drug may be supplied only in accordance with this Special Arrangement and any other Special Arrangement relating to the listed drug.

             (2)  A pharmaceutical benefit that has a drug mentioned in subsection (1) is not available for general supply on the Pharmaceutical Benefits Scheme.

Note:          The Minister has declared, under subsection 85(2A) of the Act, that the listed drug can only be supplied under a section 100 Special Arrangement.

             (3)  If the code ‘PB(100)’ is mentioned in the column in Schedule 1, headed ‘Section 100 only’ for a pharmaceutical benefit, the pharmaceutical benefit may be supplied only in accordance with this Special Arrangement and with any other Special Arrangement relating to the pharmaceutical benefit.

             (4)  A pharmaceutical benefit mentioned in subsection (3) is not available for general supply on the Pharmaceutical benefits Scheme. 

Note:          The Minister has declared, under paragraph 85(8)(a) of the Act, that this pharmaceutical benefit can only be supplied under a section 100 Special Arrangement. 

             (5)  If the code ‘C(100)’ is mentioned in the column in Schedule 1, headed ‘Section 100 only’ for a pharmaceutical benefit, and a circumstances code is mentioned for the pharmaceutical benefit in the column headed ‘Circumstances’, the pharmaceutical benefit can only be supplied in the circumstances identified in the instrument made under section 85A of the Act and in accordance with this Special Arrangement.

             (6)  A pharmaceutical benefit mentioned in subsection (5) is not available for general supply on the Pharmaceutical Benefits Scheme.

Note:          The Minister has declared, under paragraph 85(8)(b) of the Act, that 1 or more of the circumstances in which a prescription for the supply of the pharmaceutical benefit may be written are circumstances in which the benefit can only be supplied under a section 100 Special Arrangement.

Part 3Entitlement to pharmaceutical benefits

  

8  Eligible persons

             (1)  A person is eligible to receive a pharmaceutical benefit under this Special Arrangement if:

                     (a)  the person is an eligible person within the meaning of section 86 of the Act;

                     (b)  the person meets the requirements specified in the circumstances code, purposes code and conditions code (if any) mentioned for the pharmaceutical benefit, as declared by the Minister under subsection 85(2) of the Act; and

                     (c)  either;

                              (i)  the person is being treated in or at a private hospital; or

                             (ii)  the person is being treated in or at a public hospital as a non‑admitted patient, a day‑admitted patient, or an in‑patient admitted for less than 24 hours; or

                            (iii)  the person is being treated at a registered practice location.

             (2)  In this section:

private hospital has the same meaning as in the Health Insurance Act 1973.

Part 4Supply of pharmaceutical benefits

  

9  Who can supply pharmaceutical benefits

             (1)  A pharmaceutical benefit can only be supplied under this Special Arrangement by an approved hospital authority for a private hospital or public hospital:

                     (a)  on receipt of a valid prescription for an eligible patient; or

                     (b)  prior to the receipt of a valid prescription for an eligible patient, in circumstances where the eligible medical practitioner provides the prescription to the approved hospital authority within 7 days of the eligible medical practitioner treating the eligible patient with the pharmaceutical benefit.

             (2)  To avoid doubt, this section modifies section 94 of the Act in that an approved hospital authority may supply pharmaceutical benefits that are subject to this Special Arrangement for an eligible patient receiving treatment in or at the hospital of which it is the governing body or proprietor, or outside of the hospital of which it is the governing body or proprietor.

             (3)  To avoid doubt, an approved pharmacist or an approved medical practitioner cannot supply pharmaceutical benefits under this Special Arrangement.

             (4)  Under this Special Arrangement, the supplier of a pharmaceutical benefit cannot physically supply or hand over the pharmaceutical benefit directly to an eligible patient.

Part 5Administration of pharmaceutical benefits

  

10  Requirements for administering pharmaceutical benefits under this Special Arrangement

             (1)  A pharmaceutical benefit to which this Special Arrangement applies may only be administered:

                     (a)  to an eligible patient;

                     (b)  by a medical practitioner who is a eligible medical practitioner under section 11;

                     (c)  in accordance with the eligible medical practitioner’s prescription; and

                     (d)  in or at a public hospital, a private hospital or a registered practice location.

11  Eligible medical practitioner

                   For this Special Arrangement:

                   a medical practitioner is an eligible medical practitioner for administering a pharmaceutical benefit to an eligible patient, if the medical practitioner holds the specialist qualification required in the circumstances code declared by the Minister under subsection 85(2) of the Act, for treatment of that eligible patient with that pharmaceutical benefit.

12  Registered practice location

             (1)  For this Special Arrangement:

registered practice location, for an eligible medical practitioner, means a business at an address for which the eligible medical practitioner has a provider number.

             (2)  An eligible medical practitioner may have more than one registered practice location.

Part 6Payment amounts

Division 1Payments to suppliers that are approved hospital authorities for public hospitals

13  Payments to approved hospital authorities for public hospitals

             (1)  An approved hospital authority for a public hospital is entitled to be paid by the Commonwealth the amount, if any, by which the dispensed price for its supply of the pharmaceutical benefit is greater than the amount that the approved hospital authority was entitled to charge under subsection 22(2).

             (2)  The dispensed price for the supply of a pharmaceutical benefit by an approved hospital authority for a public hospital is to be worked out under Division 1 of Part 7.

             (3)  No mark‑ups may be added to the cost of a pharmaceutical benefit for which payment is claimed by an approved hospital authority for a public hospital.

Division 2—Payments to suppliers that are approved hospital authorities for private hospitals

14  Payments to approved hospital authorities for private hospitals

             (1)  An approved hospital authority for a private hospital is entitled to be paid by the Commonwealth the amount, if any, by which the dispensed price for its supply of the pharmaceutical benefit is greater than the amount that the approved hospital authority was entitled to charge under subsection 22(2).

             (2)  The dispensed price for the supply of a pharmaceutical benefit by an approved hospital authority for a private hospital is to be worked out under Division 2 of Part 7.

Part 7Dispensed price

Division 1Dispensed price for supply of a pharmaceutical benefit by a hospital authority for a public hospital

15  The dispensed price—supply by public hospital

             (1)  The dispensed price for the supply of a pharmaceutical benefit, by a hospital authority for a public hospital, is as follows:

                     (a)  if the quantity of the pharmaceutical benefit that is ordered and supplied is equal to a multiple of a pack quantity of the benefit—the sum of the approved ex‑manufacturer price or of the proportional ex‑manufacturer price for each pack quantity; or

                     (b)  if the quantity of the pharmaceutical benefit that is ordered and supplied is less than a pack quantity of the benefit—the amount calculated in accordance with section 16; or

                     (c)  if the quantity of the pharmaceutical benefit that is ordered and supplied is more than a multiple of a pack quantity of the benefit—the sum of:

                              (i)  the approved ex‑manufacturer price or the proportional ex‑manufacturer price for each pack quantity; and

                             (ii)  the amount calculated in accordance with section 16 for the remainder of the quantity supplied that is less than a pack quantity.

16  Where quantity is less than a pack quantity

             (1)  If the quantity of a pharmaceutical benefit that is ordered and supplied is less than a pack quantity of the benefit (a broken quantity), the amount mentioned in paragraph 15(1)(b) and subparagraph 15(1)(c)(ii) is to be calculated by:

                     (a)  dividing the quantity or number of units in the broken quantity by the pack quantity, expressed as a percentage to 2 decimal places; and

                     (b)  applying that percentage to the approved ex‑manufacturer price or proportional ex‑manufacturer price for the pack quantity.

Division 2Dispensed price for supply of a pharmaceutical benefit by certain suppliers

17  The dispensed price—supply by an approved hospital authority for a private hospital

             (1)  The dispensed price for the supply of a pharmaceutical benefit by an approved hospital authority for a private hospital is as follows:

                     (a)  if the quantity of the pharmaceutical benefit that is ordered and supplied is equal to a multiple of a pack quantity, the sum of:

                              (i)  the approved ex‑manufacturer price or of the proportional ex‑manufacturer price for each pack quantity, plus the mark‑up mentioned in section 18, taken to the nearest cent, with one half cent being rounded up to 1 cent; and

                             (ii)  a dispensing fee equal to the dispensing fee for the supply of a ready prepared pharmaceutical benefit, mentioned in the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the pharmaceutical benefit; or

                     (b)  if a quantity of the pharmaceutical benefit that is ordered and supplied is less than a pack quantity, the sum of:

                              (i)  the amount calculated in accordance with section 19; and

                             (ii)  a dispensing fee equal to the dispensing fee for the supply of a ready prepared pharmaceutical benefit, mentioned in the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the pharmaceutical benefit; or

                     (c)  if a quantity of the pharmaceutical benefit that is ordered and supplied is more than a multiple of a pack quantity, the sum of:

                              (i)  for each pack quantity, the approved ex‑manufacturer price or the proportional ex‑manufacturer price for the pack quantity, plus the mark‑up mentioned in section 18, taken to the nearest cent, with one half cent being counted as one cent; and

                             (ii)  the amount calculated in accordance with section 19 for the remainder of the quantity supplied that is less than a pack quantity; and

                            (iii)  a dispensing fee equal to the dispensing fee for the supply of a ready prepared pharmaceutical benefit, mentioned in the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the pharmaceutical benefit.

18  Mark‑up

                   For subparagraphs 17(1)(a)(i) and 17(1)(c)(i) and for paragraph 19(1)(a), the mark‑up for a pack quantity of a ready‑prepared pharmaceutical benefit is:

(a)  if the pack quantity for which a mark‑up is to be calculated under this section is equal to a maximum quantity of the pharmaceutical benefit, the mark‑up is the amount mentioned in the table below for the approved ex‑manufacturer price (AEMP) or for the proportional ex‑manufacturer price (PEMP) for that quantity.

This table sets out the relevant mark-up price relative to the tiers of AEMP or PEMP specified

 

                     (b)  if the pack quantity for which a mark‑up is to be calculated under this section is not equal to a maximum quantity of the pharmaceutical benefit, the mark‑up is worked out as follows:

                              (i)  if the mark‑up that would apply to the maximum quantity is shown in the table in paragraph (a) as a monetary amount—the mark‑up for the pack quantity is that monetary amount, reduced proportionately for the relative quantities; and

                             (ii)  if the mark‑up that would apply to the maximum quantity is shown in the table in paragraph (a) as a percentage of AEMP or PEMP—the mark‑up for the pack quantity is that percentage of the AEMP or PEMP for the pack quantity.

19  Where quantity is less than a pack quantity

             (1)  If the quantity of a pharmaceutical benefit that is ordered and supplied is less than a pack quantity of the benefit (a broken quantity), the amount mentioned in subparagraphs 17(1)(b)(i) and 17(1)(c)(ii) is to be calculated by:

                      (i)  adding the mark‑up mentioned in section 18 to the approved ex‑manufacturer price or to the proportional ex‑manufacturer price for the pack quantity, taking the result to the nearest cent, with one half cent being counted as 1 cent; and

                     (ii)  dividing the quantity or number of units in the broken quantity by the pack quantity, expressed as a percentage to 2 decimal places; and

                    (iii)  applying the percentage worked out under subparagraph (b) to the amount worked out under subparagraph (a).

20  Dispensing fee

                   If an eligible medical practitioner, instead of directing a repeated supply of a pharmaceutical benefit, directs the supply on one occasion of a quantity or number of units of the drug, not exceeding the total quantity or number of units that could be prescribed, if the eligible medical practitioner directed a repeated supply, the dispensed price for the supply of the pharmaceutical benefit will include only one dispensing fee.

21  Rounding up of dispensed price

                   The dispensed price for the supply of a pharmaceutical benefit will in each case be taken to the nearest cent, one half cent being counted as one cent.

Part 8Patient contributions

  

22  Patient contributions in relation to approved hospital authorities

             (1)  This section applies to an approved hospital authority for a public hospital or to a private hospital that supplies a pharmaceutical benefit.

             (2)  The approved hospital authority may charge the patient an amount equivalent to the amount that may be charged under section 87 of the Act for the supply of a pharmaceutical benefit to the patient.


Schedule 1Pharmaceutical benefits to which this Special Arrangement applies

(sections 5, and 7)

  

 

Listed Drug

Form

Manner of Administration

Brand

Section 100 only

Botulinum Toxin Type A Purified Neurotoxin Complex

Lyophilised powder for injection 100 units

Injection

Botox

D(100)

Clostridium Botulinum Type A Toxin‑

Haemagglutinin Complex

Lyophilised powder for I.M. injection 300 units

Injection

Dysport

D(100)

Clostridium Botulinum Type A Toxin–Haemagglutinin Complex

Lyophilised powder for I.M.

injection 500 units

Injection

Dysport

D(100)

Incobotulinumtoxin A

Lyophilised powder for injection 100 units

Injection

Xeomin

D(100)

 


Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

 

Endnote 2—Abbreviation key

ad = added or inserted

o = order(s)

am = amended

Ord = Ordinance

amdt = amendment

orig = original

c = clause(s)

par = paragraph(s)/subparagraph(s)

C[x] = Compilation No. x

/sub‑subparagraph(s)

Ch = Chapter(s)

pres = present

def = definition(s)

prev = previous

Dict = Dictionary

(prev…) = previously

disallowed = disallowed by Parliament

Pt = Part(s)

Div = Division(s)

r = regulation(s)/rule(s)

ed = editorial change

reloc = relocated

exp = expires/expired or ceases/ceased to have

renum = renumbered

effect

rep = repealed

F = Federal Register of Legislation

rs = repealed and substituted

gaz = gazette

s = section(s)/subsection(s)

LA = Legislation Act 2003

Sch = Schedule(s)

LIA = Legislative Instruments Act 2003

Sdiv = Subdivision(s)

(md) = misdescribed amendment can be given

SLI = Select Legislative Instrument

effect

SR = Statutory Rules

(md not incorp) = misdescribed amendment

Sub‑Ch = Sub‑Chapter(s)

cannot be given effect

SubPt = Subpart(s)

mod = modified/modification

underlining = whole or part not

No. = Number(s)

commenced or to be commenced

 

Endnote 3—Legislation history

 

Name

Registration

Commencement

Application, saving and transitional provisions

National Health (Botulinum Toxin Program) Special Arrangement 2015 (PB 87 of 2015)

1 Sept 2015 (F2015l01367)

1 Sept 2015 (s 2)

 

National Health (Botulinum Toxin Program) Special Arrangement Amendment Instrument 2017 (No. 1) (PB 8 of 2017)

1 Mar 2017 (F2017L00178)

1 Mar 2017 (s 2(1) item 1)

National Health (Botulinum Toxin Program) Special Arrangement Amendment Instrument 2018 (No. 1) (PB 90 of 2018)

27 Sept 2018 (F2018L01363)

1 Oct 2018 (s 2)

National Health (Botulinum Toxin Program) Special Arrangement Amendment Instrument 2021 (No. 1) (PB 53 of 2021)

28 May 2021 (F2021L00663)

1 June 2021 (s 2)

National Health (Botulinum Toxin Program) Amendment Special Arrangement 2022 (PB 129 of 2022)

20 Dec 2022 (F2022L01702)

1 Jan 2023 (s 2(1) item 1)

 

Endnote 4—Amendment history

 

Provision affected

How affected

Part 1

 

s 2.............................................

rep LA s 48D

s 3.............................................

rep LA s 48C

s 4.............................................

am F2018L01363; F2021L00663

Part 2

 

s 6.............................................

am F2017L00178; F2021L00663

Part 4

 

s 9.............................................

am F2022L01702

Part 9........................................

rep F2021L00663

s 23...........................................

rep F2021L00663

s 24...........................................

rep F2021L00663

s 25...........................................

rep F2021L00663

s 26...........................................

rep F2021L00663

s 27...........................................

rep F2021L00663